These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29728723)

  • 1. Pushing the limits of immune-related response: a case of "extreme pseudoprogression".
    Wong AS; Thian YL; Kapur J; Leong CN; Kee P; Lee CT; Lee MB
    Cancer Immunol Immunother; 2018 Jul; 67(7):1105-1111. PubMed ID: 29728723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
    Flippot R; Escudier B; Albiges L
    Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].
    Oppel-Heuchel H; Grimm MO
    Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
    Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
    Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.
    Rebuzzi SE; Bregni G; Grassi M; Damiani A; Buscaglia M; Buti S; Fornarini G
    Immunotherapy; 2018 Sep; 10(13):1123-1132. PubMed ID: 30236027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in renal cell carcinoma.
    Ross K; Jones RJ
    Clin Sci (Lond); 2017 Nov; 131(21):2627-2642. PubMed ID: 29079639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
    Atkins MB; Philips GK
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Krajewski KM; Albiges L; Awad MM; Bellmunt J; Hodi FS; Choueiri TK
    Cancer Immunol Res; 2016 Jan; 4(1):12-7. PubMed ID: 26589768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study.
    Bedke J; Grimm MO; Grünwald V
    Future Oncol; 2018 May; 14(11):1023-1034. PubMed ID: 29325434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
    Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
    George S; Motzer RJ; Hammers HJ; Redman BG; Kuzel TM; Tykodi SS; Plimack ER; Jiang J; Waxman IM; Rini BI
    JAMA Oncol; 2016 Sep; 2(9):1179-86. PubMed ID: 27243803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab in renal cell carcinoma.
    Michel Ortega RM; Drabkin HA
    Expert Opin Biol Ther; 2015 Jul; 15(7):1049-60. PubMed ID: 26038957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
    Joseph RW; Chatta G; Vaishampayan U
    Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.